Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01772719 | Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and… | N/A | terminated | Jan 21, 2013 | University of Louisville | Principal Investigator left institution-study not continued | Investigator |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in… | Phase 1 | terminated | Oct 20, 2015 | M.D. Anderson Cancer Center | stopped prematurely | Other (stated, no rule matched) |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced… | Phase 1 | terminated | Apr 25, 2005 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT03952832 | Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma | Phase 2 | withdrawn | May 16, 2019 | City of Hope Medical Center | Budget issues | Funding |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in… | Phase 1 / Phase 2 | terminated | Nov 13, 2014 | Ashraf Badros | Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the… | Other (stated, no rule matched) |
| NCT01783522 | Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Feb 5, 2013 | Beth Faiman | Research Cancelled | Other (stated, no rule matched) |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT02043860 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for…(BMT-02) | Phase 1 | terminated | Jan 23, 2014 | University of Illinois at Chicago | low accrual | Enrollment / accrual |
| NCT02776891 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH… | Phase 2 | withdrawn | May 18, 2016 | University of California, San Francisco | Unexpected dose production issues prevented study start up | Other (stated, no rule matched) |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | Phase 1 | terminated | Nov 11, 2015 | GlaxoSmithKline | A new study will be initiated in order to specifically investigate cardiac safety | Safety / toxicity |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | Phase 1 | terminated | Dec 20, 2017 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's…(8400-401) | Phase 1 / Phase 2 | terminated | Mar 20, 2014 | Idera Pharmaceuticals, Inc. | Lack of efficacy | Efficacy / futility |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2015 | Emory University | not stated | Not stated |
| NCT03785184 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly… | Phase 2 | withdrawn | Dec 24, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03232307 | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly… | Phase 2 | withdrawn | Jul 27, 2017 | M.D. Anderson Cancer Center | Sponsor does not wish to proceed | Other (stated, no rule matched) |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and… | Phase 1 | withdrawn | Sep 5, 2018 | Massachusetts General Hospital | Funding withdrawn by sponsor | Funding |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 3, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT03393273 | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell…(IFM2016-03) | Phase 2 | withdrawn | Jan 8, 2018 | Assistance Publique - Hôpitaux de Paris | Investigator decision in accordance with the promotor | Investigator |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | Phase 1 | terminated | Apr 27, 2010 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive… | Phase 1 | terminated | Apr 8, 2014 | Affimed GmbH | Non-favorable risk/benefit profile with studied dosing regimen | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple… | Phase 2 | terminated | Nov 7, 2017 | Yvonne Efebera | Study was discontinued due to FDA recommendations of the potential toxicities of the combination of… | Safety / toxicity |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for… | Phase 2 | terminated | Oct 30, 2015 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | Phase 1 / Phase 2 | terminated | Sep 20, 2016 | Mayo Clinic | pursuing IND | Other (stated, no rule matched) |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | Phase 2 | terminated | Nov 24, 2015 | Prothena Biosciences Ltd. | NEOD001 program terminated due to lack of clinical benefit | Efficacy / futility |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and… | Phase 2 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01927718 | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell… | N/A | terminated | Aug 23, 2013 | M.D. Anderson Cancer Center | Poor Response Rate | Other (stated, no rule matched) |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or… | Phase 1 | terminated | Jun 15, 2018 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP… | Phase 3 | terminated | Feb 1, 2011 | Hoffmann-La Roche | The study was closed by the Sponsor according to the protocol-specified minimum post-treatment… | Other (stated, no rule matched) |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | Phase 2 | terminated | May 15, 2017 | Prothena Biosciences Ltd. | NEOD001 program terminated due to lack of clinical benefit | Efficacy / futility |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Feb 27, 2019 | National Cancer Institute (NCI) | Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov | Other (stated, no rule matched) |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in… | Phase 2 | withdrawn | Jul 18, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | Phase 1 | terminated | Jun 10, 2011 | Merck Sharp & Dohme LLC | The study was terminated for business reasons. | Sponsor / business decision |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With… | Phase 2 | terminated | Jun 15, 2009 | Sirtris, a GSK Company | Study terminated.24 subjects enrolled;provided adequate data for decision making. | Enrollment / accrual |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 20, 2017 | Eureka Therapeutics Inc. | Sponsor's Decision | Sponsor / business decision |
| NCT03168100 | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule… | Phase 2 | withdrawn | May 30, 2017 | University of Arkansas | No study population. No subjects enrolled. | Enrollment / accrual |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | Phase 2 / Phase 3 | terminated | May 23, 2014 | Dr. med. Lars-Olof Muegge | Insufficient recruitment | Enrollment / accrual |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | Phase 1 | terminated | Apr 28, 2017 | Dana-Farber Cancer Institute | slow accrual | Enrollment / accrual |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | Phase 2 | terminated | Jul 14, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | MEDI-551 removed from oncology by pharmaceutical company due to change in research target. | Sponsor / business decision |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | Phase 1 / Phase 2 | terminated | Jul 4, 2013 | Adaptimmune | Sponsor Decision | Sponsor / business decision |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple… | Phase 1 / Phase 2 | terminated | Feb 25, 2011 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 18, 2019source: clinicaltrials